Brief: Plus Therapeutics Announces Read Out Of Type B Meeting With The FDA
08/01/2026 12:57
Jan 8 (Reuters) - Plus Therapeutics Inc PSTV.O: PLUS THERAPEUTICS ANNOUNCES READ OUT OF TYPE B MEETING WITH THE FDA WITH GOAL OF ACCELERATING APPROVAL OF REYOBIQ™ FOR LEPTOMENINGEAL METASTASES PLUS THERAPEUTICS INC - FDA INDICATES ACCELERATED APPROVAL MAY BE APPROPRIATE FOR LM PLUS THERAPEUTICS INC - FDA RECOMMENDS STUDY EVALUATE ENDPOINT WITH CLINICAL BENEFIT PLUS THERAPEUTICS INC - FDA CONVEYS MULTIPLE HISTOLOGIES MAY BE INCORPORATED IN TRIAL Source text: ID:nGNX86QCSM Further company coverage: PSTV.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cerenome
See all newsBrief: Cerenome Secures In-Network Agreement With Florida Blue For Cnside® Csf Tumor Cell Enumeration And Molecular Profile Tests
Plus Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Cerenome Secures In-Network Agreement With Health Care Service Corporation
Plus Therapeutics Inc expected to post a loss of 91 cents a share - Earnings Preview
Brief: Plus Therapeutics Secures Regional Coverage Agreement With Medical Mutual For CNSide Cerebrospinal Fluid Assay For Metastatic CNS Cancer